Compare ESRT & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESRT | DNA |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 826.6M | 835.7M |
| IPO Year | 2012 | 2020 |
| Metric | ESRT | DNA |
|---|---|---|
| Price | $5.42 | $8.48 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 6 | 3 |
| Target Price | $5.50 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 3.4M | 2.4M |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | N/A | ★ 46.49 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $768,270,000.00 | $170,155,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.59 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.05 | N/A |
| 52 Week Low | $3.93 | $5.37 |
| 52 Week High | $7.13 | $18.22 |
| Indicator | ESRT | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 69.58 | 40.61 |
| Support Level | $5.25 | $6.65 |
| Resistance Level | $5.85 | $10.34 |
| Average True Range (ATR) | 0.15 | 1.53 |
| MACD | 0.01 | -0.30 |
| Stochastic Oscillator | 82.91 | 2.03 |
Empire State Realty Trust Inc is a real estate investment trust (REIT) that owns and operates office, retail, and multifamily properties located in New York City, prominently in Manhattan. Its portfolio includes office and retail space as well as residential units. The company's objective is to maximize cash flow and total returns to its shareholders and to increase the value of the properties. Its reportable segments consist of a real estate segment and an Observatory segment. The majority of revenue is derived from the Real Estate segment, which includes all activities related to the ownership, management, operation, acquisition, redevelopment, repositioning and disposition of its traditional real estate assets.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.